MPLT

MapLight Therapeutics, Inc.

Nasdaq · Pharmaceutical Preparations · Inc. DE · CIK 0001770069
$27.75 -8.57% $1.3B
Insider Selling Cluster (7 insiders)7 New Institutional Positions
Vol
Market Cap$1.3B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (94%)
Inst. Holders37 funds
Inst. Value$136.5M
Inst. Activity7 buys / 2 sells
Insider Activity4B / 41S
Insider Net $-$9.4M
SEC Reports11
Press Releases2
Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. DE·CIK 0001770069·Prev Close $30.35

Recent Activity

May 19, 2026 clinical_trial_readout
Results Pending: ML-004 (IR)/(ER) tablet (Phase 2) — Completed 70d ago
Trial: ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD) Sponsor: MapLight Thera
May 19, 2026 SEC
CEO Christopher Kroeger sold $3.21M of MPLT stock on May 18, four days after the company reported Q1 2026 results (net l
CLUSTER — Impact 5/10
May 18, 2026 Insider
Kroeger Christopher A. sold 118,037 shares
Chief Executive Officer @ $27.19 ($3.2M)
May 12, 2026 SEC
Five MapLight insiders, including the CEO, CFO, CSO, and CMO, sold a total of ~$937K in open-market sales over a 7-day w
CLUSTER — Impact 3/10
May 11, 2026 Insider
Hanson Kristopher sold 284 shares
General Counsel @ $27.61 ($7.8K)
May 11, 2026 Insider
Kroeger Christopher A. sold 342 shares
Chief Executive Officer @ $27.57 ($9.4K)
May 7, 2026 SEC
MapLight Therapeutics insiders sold a combined $1.3M in open-market sales over a 7-day window, including the CEO, CFO, C
CLUSTER — Impact 5/10
Inst.
STATE STREET CORP — ADD
339,116 shares ($6.9M)

Price Targets

$38.70 +39.5% upside Strong Buy
Current $27.75 Low $30.00 Median $36.50 High $48.00 10 analysts
$30.00 $48.00

Analyst Ratings

Strong Buy94% buy · 16 analysts
5Strong Buy
10Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
Jun 2, 2026 Stifel MAINTAIN Buy → Buy
May 28, 2026 HC Wainwright & Co. REITERATE Buy → Buy
May 27, 2026 UBS INITIATE Buy
May 21, 2026 Craig-Hallum INITIATE Buy
May 4, 2026 HC Wainwright & Co. INITIATE Buy

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $-1.42 ▼ -24.9% $-1.47 — $-1.33 6
Next Q $-1.26 ▼ -16.1% $-1.35 — $-1.06 6
Current FY $-5.16 ▼ -19.0% $-5.51 — $-4.65 72% YoY 6
Next FY $-4.28 ▼ -14.6% $-5.19 — $-3.36 17% YoY 6

Latest Reports

BEARISH CLUSTER 5/10
CEO Christopher Kroeger sold $3.21M of MPLT stock on May 18, four days after the company reported Q1 2026 results (net l
May 19, 2026
NEUTRAL CLUSTER 3/10
Five MapLight insiders, including the CEO, CFO, CSO, and CMO, sold a total of ~$937K in open-market sales over a 7-day w
May 12, 2026
NEUTRAL Press 4/10
MapLight Therapeutics announced completion of enrollment in the Phase 2 ZEPHYR trial for ML-007C-MA in schizophrenia (30
May 1, 2026

Top Institutional Holders

FundValueMove
GOLDMAN SACHS GROUP INC$40.6M—
BlackRock, Inc.$27.2MNEW
VANGUARD CAPITAL MANAGEMENT LLC$14.6M—
BAKER BROS. ADVISORS LP$7.4M—
STATE STREET CORP$6.9MADD

Recent Insider Trades

DateInsiderTypeValue
May 18, 2026Kroeger ChristopherSELL$3.2M
May 11, 2026Hanson KristopherSELL$7.8K
May 11, 2026Kroeger ChristopherSELL$9.4K
May 8, 2026Kroeger ChristopherSELL$814.1K
May 7, 2026Kroeger ChristopherSELL$423.6K
37 institutional holders with $136.5M total value (6,828,180 shares) as of 2026-Q1. Top holders: GOLDMAN, BlackRock,, VANGUARD. Net buying activity: 7 institutions added/increased vs 2 reduced.

Top Institutional Holders — 2026-Q1

#FundSharesValue% of TrackedLast Move
1GOLDMAN SACHS GROUP INC1,994,873$40.6M29.7%—
2BlackRock, Inc.1,339,731$27.2M19.9%NEW
3VANGUARD CAPITAL MANAGEMENT LLC719,820$14.6M10.7%—
4BAKER BROS. ADVISORS LP364,705$7.4M5.4%—
5STATE STREET CORP339,116$6.9M5.0%ADD +47.8%
6Freestone Grove Partners LP313,957$6.4M4.7%ADD +70.8%
7BNP Paribas Asset Management Holding S.A.267,746$5.4M4.0%ADD +81.0%
8RA CAPITAL MANAGEMENT, L.P.248,294$5.0M3.7%—
9FMR LLC204,501$4.2M3.0%DOUBLED +22521.8%
10CHARLES SCHWAB INVESTMENT MANAGEMENT INC161,146$3.3M2.4%—
11LAZARD ASSET MANAGEMENT LLC142,016$2.9M2.1%TRIM -31.6%
12VANGUARD FIDUCIARY TRUST CO131,231$2.7M2.0%—
13VANGUARD PORTFOLIO MANAGEMENT LLC112,604$2.3M1.7%—
14JANUS HENDERSON GROUP PLC54,752$1.1M0.8%—
15TD ASSET MANAGEMENT INC47,768$971.1K0.7%ADD +29.2%
16WELLINGTON MANAGEMENT GROUP LLP46,208$939.4K0.7%—
17TUDOR INVESTMENT CORP ET AL36,740$746.9K0.5%—
18MORGAN STANLEY30,505$620.2K0.5%ADD +31.4%
19Nuveen, LLC23,089$469.4K0.3%—
20RHUMBLINE ADVISERS20,368$414.1K0.3%ADD +49.3%

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
STATE STREET CORPADD229,484339,116+47.8%$6.9M2026-Q1
Freestone Grove Partners LPADD183,771313,957+70.8%$6.4M2026-Q1
BNP Paribas Asset Management Holding S.A.ADD147,930267,746+81.0%$5.4M2026-Q1
FMR LLCDOUBLED904204,501+22521.8%$4.2M2026-Q1
LAZARD ASSET MANAGEMENT LLCTRIM207,494142,016-31.6%$2.9M2026-Q1
TD ASSET MANAGEMENT INCADD36,96047,768+29.2%$971.1K2026-Q1
MORGAN STANLEYADD23,22230,505+31.4%$620.2K2026-Q1
RHUMBLINE ADVISERSADD13,64220,368+49.3%$414.1K2026-Q1
BANK OF AMERICA CORP /DE/TRIM37,82018,869-50.1%$383.6K2026-Q1
BlackRock, Inc.NEW—1,095,514—$19.2M2025-Q4
VANGUARD GROUP INCNEW—869,668—$15.3M2025-Q4
10 unique insiders with 50 transactions. Net insider value: -$9.4M ($693.8K bought, $10.1M sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
May 18, 2026Kroeger Christopher A.Chief Executive OfficerSELL118,037$27.19$3.2M
May 11, 2026Hanson KristopherGeneral CounselSELL284$27.61$7.8K
May 11, 2026Kroeger Christopher A.Chief Executive OfficerSELL342$27.57$9.4K
May 8, 2026Kroeger Christopher A.Chief Executive OfficerSELL29,624$27.48$814.1K
May 7, 2026Kroeger Christopher A.Chief Executive OfficerSELL14,880$28.47$423.6K
May 7, 2026Foff Erin PennockChief Medical OfficerSELL4,321$28.52$123.2K
May 7, 2026Lillie James WoodruffChief Scientific OfficerSELL721$28.28$20.4K
May 6, 2026Kroeger Christopher A.Chief Executive OfficerSELL8,098$28.04$227.1K
May 6, 2026Foff Erin PennockChief Medical OfficerSELL8,152$28.04$228.6K
May 6, 2026Lillie James WoodruffChief Scientific OfficerSELL8,390$28.04$235.3K
May 6, 2026Setia VishwasChief Financial OfficerSELL8,496$28.04$238.2K
May 5, 2026Kroeger Christopher A.Chief Executive OfficerSELL9,544$28.12$268.4K
May 5, 2026Foff Erin PennockChief Medical OfficerSELL9,645$28.12$271.2K
May 5, 2026Lillie James WoodruffChief Scientific OfficerSELL10,132$28.12$284.9K
May 5, 2026Setia VishwasChief Financial OfficerSELL9,935$28.12$279.4K
May 4, 2026Kroeger Christopher A.Chief Executive OfficerSELL9,136$27.50$251.2K
May 4, 2026Hanson KristopherGeneral CounselSELL9,030$27.50$248.3K
May 4, 2026Foff Erin PennockChief Medical OfficerSELL9,180$27.50$252.4K
May 4, 2026Lillie James WoodruffChief Scientific OfficerSELL9,250$27.50$254.4K
May 4, 2026Setia VishwasChief Financial OfficerSELL4,803$27.36$131.4K
Apr 28, 2026GILLIS JONATHANCAAO and PAOSELL17,235$30.33$522.7K
Apr 27, 2026GILLIS JONATHANCAAO and PAOSELL7,914$28.94$229.0K
Apr 27, 2026Kreitzer AnatolChief Discovery OfficerSELL8,346$28.96$241.7K
Apr 16, 2026Lillie James WoodruffChief Scientific OfficerSELL686$27.01$18.5K
Apr 16, 2026Hanson KristopherGeneral CounselSELL73$27.01$2.0K
Apr 16, 2026Foff Erin PennockChief Medical OfficerSELL288$27.01$7.8K
Apr 16, 2026Setia VishwasChief Financial OfficerSELL29$27.01$783.29
Apr 16, 2026Kroeger Christopher A.Chief Executive OfficerSELL2,477$27.01$66.9K
Apr 15, 2026GILLIS JONATHANCAAO and PAOSELL3,590$26.61$95.5K
Apr 15, 2026Malenka Robert C.DirectorSELL8,593$26.90$231.2K
Apr 15, 2026Setia VishwasChief Financial OfficerSELL2,806$26.87$75.4K
Apr 15, 2026Foff Erin PennockChief Medical OfficerSELL2,044$26.84$54.9K
Apr 15, 2026Hanson KristopherGeneral CounselSELL1,529$26.80$41.0K
Apr 15, 2026Kroeger Christopher A.Chief Executive OfficerSELL9,135$26.93$246.0K
Apr 15, 2026Lillie James WoodruffChief Scientific OfficerSELL1,730$26.82$46.4K
Apr 15, 2026Kreitzer AnatolChief Discovery OfficerSELL3,316$26.61$88.2K
Feb 24, 2026Malenka Robert C.DirectorSELL736$18.15$13.4K
Feb 23, 2026Malenka Robert C.DirectorSELL10,788$18.39$198.4K
Feb 20, 2026Pavlov GeorgeDirectorBUY9,920$17.86$177.2K
Feb 20, 2026Malenka Robert C.DirectorSELL2,195$18.03$39.6K
Feb 19, 2026Pavlov GeorgeDirectorBUY4,422$17.57$77.7K
Feb 18, 2026Pavlov GeorgeDirectorBUY10,658$17.48$186.3K
Feb 11, 2026Malenka Robert C.DirectorSELL241$18.00$4.3K
Feb 10, 2026Garnett Timothy JohnDirectorBUY14,124$17.89$252.7K
Feb 10, 2026Malenka Robert C.DirectorSELL6,622$18.12$120.0K
Feb 5, 2026Kroeger Christopher A.Chief Executive OfficerAWARD23,145——
Feb 5, 2026Kroeger Christopher A.Chief Executive OfficerAWARD93,955——
Feb 5, 2026Foff Erin PennockChief Medical OfficerAWARD13,360——
Feb 5, 2026Foff Erin PennockChief Medical OfficerAWARD54,240——
Feb 5, 2026Hanson KristopherGeneral CounselAWARD7,730——
11 SEC filing reports analyzed. Sentiment: 0 bullish, 3 bearish, 0 mixed, 8 neutral. Avg impact: 3.4/10.
BEARISH CLUSTER 5/10
CEO Christopher Kroeger sold $3.21M of MPLT stock on May 18, four days after the company reported Q1
May 19, 2026
NEUTRAL CLUSTER 3/10
Five MapLight insiders, including the CEO, CFO, CSO, and CMO, sold a total of ~$937K in open-market
May 12, 2026
BEARISH CLUSTER 5/10
MapLight Therapeutics insiders sold a combined $1.3M in open-market sales over a 7-day window, inclu
May 7, 2026
NEUTRAL 144 2/10
Officer Christopher Kroeger filed Form 144 to sell 236,470 shares (~$7.3M) under a 10b5-1 plan adopt
May 4, 2026
NEUTRAL 144 3/10
Officer Lillie James Woodruff filed a Form 144 to sell 52,428 shares of common stock valued at appro
May 4, 2026
NEUTRAL 144 3/10
Officer Jonathan Gillis filed a Form 144 indicating intent to sell 69,835 shares of MapLight Therape
Apr 27, 2026
BEARISH CLUSTER 6/10
Multiple executives at MapLight Therapeutics, including CEO Christopher Kroeger and CFO Vishwas Seti
Apr 17, 2026
NEUTRAL 144 3/10
Jonathan Gillis, an officer of MapLight Therapeutics, filed a Form 144 to notify intent to sell up t
Apr 15, 2026
NEUTRAL 144 3/10
Robert C. Malenka, a director of MapLight Therapeutics, filed a Form 144 notifying intent to sell 8,
Apr 15, 2026
NEUTRAL 144 2/10
Christopher Kroeger, an officer of MapLight Therapeutics, filed a Form 144 to notify intent to sell
Apr 15, 2026
NEUTRAL 144 2/10
Lillie James Woodruff, an officer of MapLight Therapeutics (MPLT), filed a Form 144 notifying intent
Apr 15, 2026
NEUTRAL 4/10
MapLight Therapeutics announced completion of enrollment in the Phase 2 ZEPHYR trial for ML-007C-MA
May 1, 2026
NEUTRAL 5/10
MapLight Therapeutics reported financial results for Q4 and full year 2025, highlighting a significa
Mar 26, 2026
Current analyst consensus: Strong Buy (94% buy). Based on 16 analysts: 5 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$38.70 mean target +39.5% upside Strong Buy (1.18)
$30.00 Low $48.00 High
MetricValue
Current Price$27.75
Target Low$30.00
Target Mean$38.70
Target Median$36.50
Target High$48.00
# Analysts10
RecommendationStrong Buy (1.18)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
 $-1.42 $-1.47 $-1.33 — -24.9% — $0.0B — 6
Next Q
2026-09-30
 $-1.26 $-1.35 $-1.06 — -16.1% — $0.0B 0.0% 6
Current FY
2026-12-31
 $-5.16 $-5.51 $-4.65 72.2% -19.0% — $0.0B 0.0% 6
Next FY
2027-12-31
 $-4.28 $-5.19 $-3.36 17.0% -14.6% — $0.0B 0.0% 6

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$-1.415
7d ago$-1.322-0.093
30d ago$-1.133-0.282
60d ago$-0.987-0.428
90d ago$0.000-1.415
7 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 6 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
Jun 2, 2026 Stifel MAINTAIN Buy Buy
May 28, 2026 HC Wainwright & Co. REITERATE Buy Buy
May 27, 2026 UBS INITIATE — Buy
May 21, 2026 Craig-Hallum INITIATE — Buy
May 4, 2026 HC Wainwright & Co. INITIATE — Buy
Apr 8, 2026 Needham INITIATE — Buy
Apr 7, 2026 TD Cowen INITIATE — Buy
Mar 19, 2026 Canaccord Genuity INITIATE — Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 202651010094%
May 1, 20265710092%
Apr 1, 20265510091%
Mar 1, 20265410090%
Feb 1, 20265410090%
Jan 1, 20265410090%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

May 20, 2026
Clinical Trial
ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)
Phase Phase 2 — COMPLETED
May 19, 2026
clinical_trial_readout
Results Pending: ML-004 (IR)/(ER) tablet (Phase 2) — Completed 70d ago
Trial: ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD) Sponsor: MapLight Therapeutics Phase: Phase 2 | Completed: 2026-03-10 Con
May 1, 2026
fda
MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
<p>SAN FRANCISCO and BOSTON, May 01, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company
Mar 26, 2026
earnings
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
<p>SAN FRANCISCO and BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical compa
Mar 23, 2026
short_interest
FTD: MPLT — 70,309 shares ($1.2M) failed to deliver
Settlement: 20260323, Price: $17.56, FTD Value: $1,234,626.04, MAPLIGHT THERAPEUTICS INC COM
Mar 2, 2026
earnings_calendar
MPLT Q4 2025 Earnings Scheduled — 2026-03-02
Feb 24, 2026
short_interest
FTD: MPLT — 68,938 shares ($1.3M) failed to deliver
Settlement: 20260224, Price: $18.30, FTD Value: $1,261,565.4, MAPLIGHT THERAPEUTICS INC COM
Feb 17, 2026
short_interest
FTD: MPLT — 46,055 shares ($0.8M) failed to deliver
Settlement: 20260217, Price: $17.22, FTD Value: $793,067.1, MAPLIGHT THERAPEUTICS INC COM